Primary esophageal melanoma remains a rare entity with less than 350 case reports noted in the current literature. This diagnosis is associated with a poor prognosis and early detection and management remains fundamental. In this report, we examine the case of an 80-year-old female who presented with a 1-year course of progressive dysphagia and weight loss. Investigations revealed a primary esophageal melanoma with no evidence of metastases. Pathology did not identify any targetable markers for systematic therapy and thus the patient successfully underwent a minimally invasive esophagectomy. Her postoperative course involved endoscopic esophageal dilatations due to an anastomotic stricture, as well as primary lung adenocarcinoma treated with radiotherapy but has otherwise remained without evidence of melanoma recurrence after 25 months from her surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291394 | PMC |
| http://dx.doi.org/10.2217/mmt-2022-0002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention strategies of esophageal stenosis after endoscopic resection for superficial esophageal cancer: a Bayesian network meta-analysis.
Int J Surg
January 2025
Department of Geriatrics, Zhongshan Hospital Xiamen University, Fujian, People's Republic of China.
Introduction: What interventions effectively prevent postoperative stenosis following endoscopic resection (ER) of superficial esophageal cancer? This study aimed to identify effective interventions or combinations through a systematic review and network meta-analysis.
Methods: Six databases were systematically searched for eligible studies up to 30 April 2023, on interventions to prevent esophageal stenosis post-ER. Odds ratios (ORs) evaluated stenosis rate (primary outcome) and complications (secondary outcome), while mean differences (MD) evaluated endoscopic balloon dilatation (EBD) sessions post-stenosis.
Global, regional, and national burden of esophageal cancer using the 2019 global burden of disease study.
Sci Rep
January 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Esophageal cancer, with its aggressive nature and high mortality, poses diverse epidemiological challenges worldwide. Over the past three decades, esophageal cancer has exhibited a substantial global burden, marked by a significant increase in absolute numbers, contrasting with a decline in age-standardized metrics. Prevalence nearly doubled, reaching 0.
View Article and Find Full Text PDFSurgical and Long-term Outcomes of Combined Organ Resection for Esophageal Cancer Invading Adjacent Organs: Experience of 90 Consecutive Cases.
J Thorac Cardiovasc Surg
January 2025
Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, 565-0871, Japan.
Objective: To evaluate the feasibility of and long-term survival with combined organ resection for esophageal cancer (EC).
Background: The optimal treatment strategy for EC that is invading adjacent organs is not established.
Methods: Ninety patients with EC invading adjacent organs who underwent combined organ resection after induction treatments during 2003-2023 in our institute were eligible for the study.
Immunonutrition to improve the quality of life of upper gastrointestinal cancer patients undergoing neoadjuvant treatment prior to surgery (NEOIMMUNE): double-blind randomized controlled multicenter clinical trial.
Dis Esophagus
January 2025
Department of Digestive and Oncological Surgery, Claude Huriez Hospital, Chu Lille, Lille, France.
Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.
Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.
Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma.
Eur J Surg Oncol
January 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Introduction: A precise preoperative tumor monitoring method that reflects tumor burden during neoadjuvant treatment is required to guide individualized perioperative treatment strategies for esophageal squamous cell carcinoma (ESCC). This study examined the clinical significance of preoperative circulating tumor DNA (ctDNA) in the plasma of patients undergoing neoadjuvant chemotherapy (NAC) followed by esophagectomy.
Materials And Methods: Plasma samples were collected longitudinally for ctDNA analysis as well as genomic DNA from primary lesions from patients with histologically confirmed ESCC who received neoadjuvant chemotherapy (NAC) followed by subtotal esophagectomy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!